2010
A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors.
Kunz P, Kuo T, Zahn J, Kaiser H, Norton J, Visser B, Longacre T, Ford J, Balise R, Fisher G. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. Journal Of Clinical Oncology 2010, 28: 4104-4104. DOI: 10.1200/jco.2010.28.15_suppl.4104.Peer-Reviewed Original Research
2008
A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary results
Kunz P, Kuo T, Kaiser H, Norton J, Longacre T, Ford J, Fisher G. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary results. Journal Of Clinical Oncology 2008, 26: 15502-15502. DOI: 10.1200/jco.2008.26.15_suppl.15502.Peer-Reviewed Original ResearchPhase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer
Cabebe E, Kuo T, Koong A, Welton M, Shelton A, Kunz P, Ford J, Sikic B, Kaiser H, Rogers J, Fisher G. Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer. Journal Of Clinical Oncology 2008, 26: 15019-15019. DOI: 10.1200/jco.2008.26.15_suppl.15019.Peer-Reviewed Original Research